EloraTZP versus tirzepatide for excess weight and type 2 diabetes
Tests EloraTZP against tirzepatide in obesity with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Key facts
- Where
- Campinas, Curitiba, Porto Alegre, Rio de Janeiro, and São Paulo, BrazilSee the 6 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who have obesity or overweight and have tried to lose weight by diet without success.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Type 2 diabetes with a BMI of ≥27 kg/m2 at screening
- Earlier treatment
- Must have tried at least 1 diet effort to lose weight that did not work. Must not have taken weight-loss medicines, amylin, GLP-1 or GIP drugs, DPP-4 inhibitors or insulin in the 90 days before screening. Must not have had weight-loss surgery, endoscopic procedures or device-based therapy (some exceptions are listed in the record).
Main reasons for not taking part
- Type 1 diabetes
- Heart attack, stroke, coronary artery revascularization, unstable angina or hospitalization for heart failure in the 90 days before screening
- Class IV congestive heart failure (New York Heart Association)
- Prior or planned surgery for obesity
- Weight-loss medicines or alternative remedies in the 90 days before screening
Read by machine on 9 November 2026.
Where in Brazil
- Centro de Pesquisa Sao LucasCampinas, BrazilNot yet recruiting
- Cline Research CenterCuritiba, BrazilNot yet recruiting
- Nucleo de Pesquisa Clínica do Rio Grande do SulPorto Alegre, BrazilNot yet recruiting
- IBPClin - Instituto Brasil de Pesquisa ClínicaRio de Janeiro, BrazilNot yet recruiting
- CEPIC - Centro Paulista de Investigação ClínicaSão Paulo, BrazilNot yet recruiting
- CPCLINSão Paulo, BrazilNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07881458EU 2026-527230-31-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes.Read full original descriptionShow less
A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity or Overweight and Type 2 Diabetes
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes.
Participation in the study will last about 2 years.
Inclusion: Have type 2 diabetes; Have a stable self-reported body weight (<5% body weight change) for 90 days prior to screening; Have a BMI of ≥27 kg/m2 at screening; Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have taken any of the following within 90 days prior to screening; medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including compounded therapies; dipeptidyl peptidase 4 (DPP-4) inhibitors, and; insulin; Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.